On March 21, 2026, DAFNA Capital filed with the SEC, detailing modifications to its holdings in the iShares Biotechnology ETF.
These adjustments are part of a larger strategy aimed at optimizing their biotech portfolio.
The iShares Biotechnology ETF continues to play a significant role in DAFNA's investment framework, despite the recent changes.